Skyhawk Therapeutics, Inc. announced that it has expanded its strategic collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to discover, develop and commercialize small molecules that modulate RNA splicing. The collaboration now spans four disease areas: neurodegeneration, oncology, autoimmunity and metabolic diseases.